Printer Friendly

ROBERT RUARK, FORMER MERCK EXECUTIVE, JOINS BOARD OF UNIGENE LABORATORIES

 FAIRFIELD, N.J., Oct. 5 /PRNewswire/ -- Unigene Laboratories, Inc. (NASDAQ: UGNE) announced today the appointment of Robert G. Ruark to the company's board of directors.
 Mr. Ruark is an attorney with extensive experience in international licensing and business development accumulated during a 25-year career with Merck. Prior to accepting early retirement from Merck this year, he had served as Associate General Counsel and vice president of administration of the Human Health Division. During his tenure at Merck he had direct responsibility for various activities including several major joint ventures and acquisitions, hundreds of licensing agreements and divisional capital planning.
 "Bob's direct participation in establishing such a wide variety of strategic relationships will be of great value to Unigene as we seek to conclude such relationships with pharmaceutical companies for the commercial development of calcitonin," said Dr. Warren Levy, president of Unigene. "We expect that he will be intimately involved in strategy development and implementation in these areas in his dual role as consultant and director."
 Mr. Ruark will complete the term of Luther Smithson, who has resigned from the board of directors for personal reasons. "Bud Smithson's knowledge of the pharmaceutical and biotechnology industries was instrumental in helping to direct the company's activities," said Dr. Levy. "He has served Unigene with distinction and we wish him well in his future endeavors."
 Unigene Laboratories has developed a proprietary process capable of producing peptide hormones for the treatment of various diseases and disorders. The company's primary focus is calcitonin, a drug used to treat osteoporosis with worldwide sales of approximately $1 billion. Unigene is currently building a calcitonin manufacturing facility in Boonton, N.J. which is targeted for completion around the middle of 1994.
 -0- 10/5/93
 /CONTACT: Warren P. Levy, Ph.D., president of Unigene Laboratories, Inc., 201-882-0860/
 (UGNE)


CO: Unigene Laboratories, Inc. ST: New Jersey IN: MTC SU: PER

WB-OS -- NY045 -- 8878 10/05/93 12:57 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Oct 5, 1993
Words:319
Previous Article:BUTLER INTERNATIONAL, INC. ACQUIRES CERTAIN BUSINESS ASSETS IN CALIFORNIA
Next Article:RELIANCE GROUP HOLDINGS DECLARES QUARTERLY DIVIDEND ON COMMON STOCK
Topics:

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters